Department of Ophthalmology, Seoul National University College of Medicine, Seoul, Korea.
Laboratory of Ocular Regenerative Medicine and Immunology, Seoul Artificial Eye Center, Seoul National University Hospital Biomedical Research Institute, Seoul, Korea.
Xenotransplantation. 2017 May;24(3). doi: 10.1111/xen.12298. Epub 2017 Apr 10.
Corneal xenotransplantation is an effective solution for the shortage of human donor corneas, and the porcine cornea may be a suitable candidate for the donor cornea because of its optical similarity with humans. However, it is necessary to administer additional immunosuppressants to overcome antigenic differences. We aimed to investigate the feasibility of porcine corneas with anti-CD40 antibody-mediated costimulation blockade in a clinically applicable pig-to-non-human primate corneal xenotransplantation model.
Five Chinese rhesus macaques underwent deep-lamellar corneal transplantation using clinically acceptable sized (7.5 mm diameter) porcine corneal grafts. The anti-CD40 antibody was intravenously administered on a programmed schedule. Graft survival, central corneal thickness, and intraocular pressure were evaluated. Changes in effector and memory T and B cell subsets and anti-αGal and donor-specific antibodies were investigated in the blood, and the changes in complement levels in the aqueous humor and blood were evaluated. Memory cell profiles in the anti-CD40 antibody-treated group were compared with those from the anti-CD154 antibody-treated group or rejected controls presented in our previous report. The changes in anti-αGal, non-αGal, and donor-specific antibodies after 6 months were compared with baseline values.
Anti-CD40 antibody-mediated costimulation blockade resulted in the successful survival of xenocorneal grafts (>389, >382, >236, >201, and >61 days), with 80% reaching 6 months of survival. Injection of anti-CD40 antibody considerably reduced the infiltration of inflammatory cells into the grafts and significantly blocked the complement response in the aqueous humor (P=.0159, Mann-Whitney U test). Systemic expansion of central or effector memory T cells was abrogated in the anti-CD40 antibody-treated primates compared with those in the rejected controls (P<.05, Mann-Whitney U test) or those in the anti-CD154 antibody-treated primates (P>.05, Mann-Whitney U test). The levels of anti-αGal, non-αGal, and donor-specific antibodies at 6 months were not significantly increased compared with baseline levels (P>.05, Wilcoxon signed rank test).
An anti-CD40 antibody-mediated blockade appears to be effective immunosuppressive approach for porcine corneal deep-lamellar xenotransplantation in primates.
角膜异种移植是解决人类供体角膜短缺的有效方法,而猪角膜可能是供体角膜的合适候选者,因为它与人的光学相似性。然而,有必要使用额外的免疫抑制剂来克服抗原差异。我们旨在研究在临床适用的猪到非人类灵长类动物角膜异种移植模型中,用抗 CD40 抗体介导的共刺激阻断来实现猪角膜的可行性。
5 只中国猕猴接受了临床可接受大小(7.5 毫米直径)的猪角膜移植物的深板层角膜移植。抗 CD40 抗体按程序计划静脉给药。评估移植物存活率、中央角膜厚度和眼内压。研究了血液中效应和记忆 T 和 B 细胞亚群以及抗-αGal 和供体特异性抗体的变化,并评估了房水和血液中补体水平的变化。将抗 CD40 抗体治疗组的记忆细胞谱与我们之前报告中的抗 CD154 抗体治疗组或排斥对照进行比较。将 6 个月后抗-αGal、非-αGal 和供体特异性抗体的变化与基线值进行比较。
抗 CD40 抗体介导的共刺激阻断导致异种角膜移植物成功存活(>389、>382、>236、>201 和>61 天),80%的移植物存活时间达到 6 个月。抗 CD40 抗体的注射大大减少了炎性细胞浸润到移植物中,并显著阻断了房水中的补体反应(P=.0159,Mann-Whitney U 检验)。与排斥对照相比(P<.05,Mann-Whitney U 检验)或与抗 CD154 抗体治疗的灵长类动物相比(P>.05,Mann-Whitney U 检验),抗 CD40 抗体治疗的灵长类动物中中央或效应记忆 T 细胞的全身扩增被阻断。与基线水平相比,6 个月时抗-αGal、非-αGal 和供体特异性抗体的水平没有显著增加(P>.05,Wilcoxon 符号秩检验)。
抗 CD40 抗体介导的阻断似乎是灵长类动物猪角膜深板层异种移植的有效免疫抑制方法。